These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31279056)

  • 1. Predicting the solubility enhancement of amorphous drugs and related phenomena using basic thermodynamic principles and semi-empirical kinetic models.
    Skrdla PJ; Floyd PD; Dell'Orco PC
    Int J Pharm; 2019 Aug; 567():118465. PubMed ID: 31279056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicted amorphous solubility and dissolution rate advantages following moisture sorption: Case studies of indomethacin and felodipine.
    Skrdla PJ; Floyd PD; Dell'Orco PC
    Int J Pharm; 2019 Jan; 555():100-108. PubMed ID: 30448307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the maximal solubility advantage of drug salts.
    Skrdla PJ
    Int J Pharm; 2021 Feb; 595():120228. PubMed ID: 33484924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical Estimation of Amorphous Solubility Enhancement Using Thermoanalytical Data: Determination of the Amorphous/Crystalline Solubility Ratio for Pure Indomethacin and Felodipine.
    Skrdla PJ; Floyd PD; Dell'orco PC
    J Pharm Sci; 2016 Sep; 105(9):2625-2630. PubMed ID: 27372548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2010 Mar; 99(3):1254-64. PubMed ID: 19697391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solubility Advantage (and Disadvantage) of Pharmaceutical Amorphous Solid Dispersions.
    Huang S; Mao C; Williams RO; Yang CY
    J Pharm Sci; 2016 Dec; 105(12):3549-3561. PubMed ID: 27692620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Res; 2010 Dec; 27(12):2704-14. PubMed ID: 20859662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the true solubility advantage for amorphous pharmaceuticals?
    Hancock BC; Parks M
    Pharm Res; 2000 Apr; 17(4):397-404. PubMed ID: 10870982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutual Impact of Phase Separation/Crystallization and Water Sorption in Amorphous Solid Dispersions.
    Luebbert C; Wessner M; Sadowski G
    Mol Pharm; 2018 Feb; 15(2):669-678. PubMed ID: 29309155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
    Baghel S; Cathcart H; O'Reilly NJ
    J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Physical Stability of PVP- and PVPVA-Amorphous Solid Dispersions.
    Lehmkemper K; Kyeremateng SO; Heinzerling O; Degenhardt M; Sadowski G
    Mol Pharm; 2017 Jan; 14(1):157-171. PubMed ID: 28043133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Assessment of Miniaturized Screening Approaches for Selection of Polymers for Amorphous Drug Stabilization.
    Banda A; Manchanda A; Zhang W; Alba GM; Nagapudi K
    J Pharm Sci; 2018 Mar; 107(3):897-908. PubMed ID: 29155235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solubility advantage from amorphous etoricoxib solid dispersions.
    Dani P; Puri V; Bansal AK
    Drug Dev Ind Pharm; 2014 Jan; 40(1):92-101. PubMed ID: 23301771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation into the crystallization tendency/kinetics of amorphous active pharmaceutical ingredients: A case study with dipyridamole and cinnarizine.
    Baghel S; Cathcart H; Redington W; O'Reilly NJ
    Eur J Pharm Biopharm; 2016 Jul; 104():59-71. PubMed ID: 27108783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glass-Transition Temperature of the β-Relaxation as the Major Predictive Parameter for Recrystallization of Neat Amorphous Drugs.
    Kissi EO; Grohganz H; Löbmann K; Ruggiero MT; Zeitler JA; Rades T
    J Phys Chem B; 2018 Mar; 122(10):2803-2808. PubMed ID: 29498523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of supersaturation of amorphous pharmaceuticals: nonlinear rate of supersaturation generation regulated by matrix diffusion.
    Sun DD; Lee PI
    Mol Pharm; 2015 Apr; 12(4):1203-15. PubMed ID: 25775257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved kinetics approach to describe the physical stability of amorphous solid dispersions.
    Yang J; Grey K; Doney J
    Int J Pharm; 2010 Jan; 384(1-2):24-31. PubMed ID: 19786081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility.
    Gupta P; Chawla G; Bansal AK
    Mol Pharm; 2004; 1(6):406-13. PubMed ID: 16028352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
    Qian F; Huang J; Hussain MA
    J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.